Exciting New Vaccine for Pancreatic Cancer Shows Promise
A groundbreaking new vaccine aimed at preventing pancreatic cancer has shown positive results in an early study conducted by researchers at Johns Hopkins School of Medicine in Baltimore, Maryland.
This phase 1 trial, published in the journal Cancer Discovery, focused on an experimental vaccine named mKRAS-VAX, enrolling 20 participants who are at an increased risk for pancreatic ductal adenocarcinoma (PDAC), the most common and aggressive type of pancreatic cancer. Notably, these individuals had not yet been diagnosed with the disease but had abnormal findings, often in the form of pancreatic cysts.
The study involved participants receiving four doses of the vaccine at specific intervals—weeks one, three, and five, followed by a booster shot at week 13. This vaccine was particularly designed to target six common mutations of the KRAS gene, which are responsible for driving over 90% of PDAC cases.
The results were promising: 90% of participants developed an immune response specifically targeting the mutant KRAS. On average, there was an 18-fold increase in immune activity, with half of the participants responding to all six mutations.
Additionally, the vaccine helped generate two types of T cells. One type is designed to attack abnormal cells, while the other aids in maintaining long-term immune memory. Most participants only experienced mild side effects, such as soreness at the injection site and temporary flu-like symptoms.
While the primary aim of the trial was to assess safety rather than effectiveness, the follow-up period of around 16.5 months revealed that no participants developed pancreatic cancer. Encouragingly, 37.5% of the vaccinated individuals experienced a reduction or complete disappearance of the pancreatic cysts that initially raised their risk for the disease.
Dr. Neeha Zaidi, an associate professor of oncology at Johns Hopkins, emphasized the vaccine’s long-lasting immune response, which is crucial for preventing cancer. She noted that its safety and toleration make it suitable for larger studies aimed at cancer prevention.
Co-author Dr. Michael G. Goggins highlighted the potential of the vaccine to stabilize or even regress pancreatic cysts, although he stressed the need for larger studies to confirm these findings.
The study acknowledged its limitations, including the small sample size and its design focused on safety over clinical effectiveness.
Dr. Elizabeth Jaffee, another senior author, reiterated the importance of developing effective strategies for cancer prevention, especially for fast-growing cancers where early detection methods are not yet effective.
Jaffee called for increased funding to advance research in creating better vaccines, determining optimal targets, and establishing the best timing for vaccinations.
This initial study marks a significant step toward the potential use of vaccines in thwarting pancreatic cancer in high-risk individuals.
